You can view 1 more answer this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Amgen Inc. (AMGN $294.70)
- $294.70 P/E (TTM): 23.84X Cap: $157.20B
- View AMGN Profile
- View Questions on AMGN
Merck & Company Inc. (MRK $84.96)
- $84.96 P/E (TTM): 13.35X Cap: $215.50B
- View MRK Profile
- View Questions on MRK
AbbVie Inc 0.500% Senior Notes 2021 (ABBV.21C)
- P/E (TTM): 44.76X
- View ABBV.21C Profile
- View Questions on ABBV.21C
Harvest Healthcare Leaders Enhanced Income ETF (HHLE $8.82)
- $8.82 P/E (TTM): 23.08X Cap: $73M
- View HHLE Profile
- View Questions on HHLE

Q: Hello 5i, I am up quite a bit on MRK, ABBVIE and HHLE. In answer to a question on MRK by Michael on Jan 22 you wrote "We would take a look at AMGN as an alternative to MRK". With the success I have with MRK et al. is MRK a sell to be replaced by AMGN now or is MRK still a keeper for now. Value investor.
Stanley

Asked by STANLEY on January 23, 2025

5i Research Answer:

We would still be comfortable with MRK overall and just offered AMGN as an alternative. MRK has been disappointing but still has potential and we would consider it a 'safe' name within the sector.

Let us help YOU reach your financial goals today!

Start your FREE trial today and enjoy all the benefits of a 5i Membership including:

Access to a team of experts ready to answer your investments question
Instant access to over 100,000 archived questions
A community of like-minded investors
Peace of mind knowing that 5i Research has only YOUR best interests in mind

First Name *

Last Name *

E-mail *

Password *

I have read and agree to the Terms of Use